Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nerispirdine · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Nerispirdine 50mg | EXPERIMENTAL | Nerispirdine 50mg once daily for 14 weeks |
| Nerispirdine 100mg | EXPERIMENTAL | Nerispirdine 100mg once daily for 14 weeks |
| Nerispirdine 200mg | EXPERIMENTAL | Nerispirdine 200mg once daily for 14 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo for Nerispirdine once daily for 14 weeks |
| Sequence 1 | EXPERIMENTAL | placebo,1 day treatment period 1 50 mg Nerispirdine, 1 day treatment period 2 400 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 2 | EXPERIMENTAL | placebo,1 day treatment period 1 400 mg Nerispirdine, 1 day treatment period 2 50 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 3 | EXPERIMENTAL | 50 mg Nerispirdine, 1 day treatment period 1 placebo, 1 day treatment period 2 400 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 4 | EXPERIMENTAL | 50 mg Nerispirdine, 1 day treatment period 1 400 mg Nerispirdine, 1 day treatment period 2 placebo, 1 day treatment period 3 |
| Sequence 5 | EXPERIMENTAL | 400 mg Nerispirdine, 1 day treatment period 1 placebo, 1 day treatment period 2 50 mg Nerispirdine, 1 day treatment period 3 |
| Sequence 6 | EXPERIMENTAL | 400 mg Nerispirdine, 1 day treatment period 1 50 mg Nerispirdine, 1 day treatment period 2 placebo, 1 day treatment period 3 |
| Name | Type | Description |
|---|---|---|
| Nerispirdine | DRUG | tablet, oral administration |
| placebo | DRUG | tablet, oral administration |
Inclusion Criteria: * Clinically definite MS (according to McDonald criteria), Exclusion Criteria: * Multiple sclerosis exacerbation or clinical relapse within 6-month prior to the screening visit. * Subject who is not able to complete two trials of a timed 25 foot walk, with or without an assist...
Nerispirdine is an investigational small molecule being studied for the treatment of Multiple Sclerosis. It is in Phase 2 clinical development and has been evaluated in patients with this condition, including those with optic nerve involvement. Nerispirdine is not approved and remains under clinical investigation.
Nerispirdine is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with Multiple Sclerosis.
Nerispirdine is in Phase 2 clinical development. Two Phase 2 trials have been completed, with a total of 436 participants enrolled. The drug is investigational and has not been approved for any use. Both trials were randomized, double-blind, and placebo-controlled.
Nerispirdine has been studied in two completed Phase 2 trials. NCT00772525 evaluated single oral doses on visual function in 31 patients with Multiple Sclerosis and optic neuritis. NCT00811902 assessed efficacy, safety, and tolerability in 405 patients with Multiple Sclerosis across multiple countries.
Nerispirdine is a distinct investigational small molecule developed by Sanofi. It is not known to be the same as any other marketed drug. Its mechanism of action has not been publicly detailed, and it is being studied specifically for its potential effects in Multiple Sclerosis.